| Record ID | marc_records_scriblio_net/part16.dat:86278833:1261 |
| Source | Scriblio |
| Download Link | /show-records/marc_records_scriblio_net/part16.dat:86278833:1261?format=raw |
LEADER: 01261nam 2200289 a 4500
001 82603822
003 DLC
005 19990716000000.0
008 830906s1982 dcua b f000 0 eng c
010 $a 82603822
040 $aDGPO/DLC$cDLC$dDLC
043 $an-us---
050 00 $aKF27$b.G664 1982c
082 00 $a353.0077/84$219
086 0 $aY 4.G 74/7:D 84/14
110 1 $aUnited States.$bCongress.$bHouse.$bCommittee on Government Operations.$bIntergovernmental Relations and Human Resources Subcommittee.
245 14 $aThe regulation of new drugs by the Food and Drug Administration :$bthe new drug review process : hearings before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-seventh Congress, second session, August 3 and 4, 1982.
260 $aWashington :$bU.S. G.P.O.,$c1982.
300 $avii, 688 p. :$bill. ;$c24 cm.
504 $aIncludes bibliographical references.
500 $a[4 cds]
500 $aItem 1016-A, 1016-B (microfiche)
610 10 $aUnited States.$bFood and Drug Administration.
650 0 $aDrugs$xLaw and legislation$zUnited States.
650 0 $aPharmacy$xLaw and legislation$zUnited States.
650 0 $aDrugs$zUnited States$xTesting.
740 4 $aThe new drug review process.